Abstract The aim of this study is to evaluate the efficacy and safety of prolonged therapy with low-dose clarithromycin in patients with chronic rhinosinusitis with polyps (CRSwP) after endoscopic sinus surgery (ESS). A total of 10 patients with CRSwP were identified and subjected to bilateral ESS. In post-operative patients they were treated with nasal wash with saline solution and steroid sprays (beclomethasone). During follow-up, after 30-40 days after the operation (M = 35.4 SD = ?4.33), patients reported a worsening of symptoms with onset of nasal obstruction; reduction/loss of smell; headache; onset of viscous secretions and therefore all patients continued therapy with saline nasal irrigation, topical steroid therapy and started macrolide (clarithromycin 500 mg/pill: 1 pill/day for 3 days a week for 1 month). 22-item SinoNasal Outcome Test (SNOT-22) and a score to the endoscopic evaluation (endoscopic appearance score, EAS) before and after treatment were performed to evaluate efficacy of treatment. The results of the SNOT-22 and EAS showed statistically significant improvements (p \ 0.05) for some parameters such as: the need to blow nose, sneezing, hyposmia, viscous mucous secretions about the SNOT-22 and reduction of secretions and edema of the nasal mucosa about the EAS. The preliminary results of our study show that the low-dose clarithromycin for a period of 1 month can improve patient complaints with CRSwP not only through the antibacterial properties but also for the immunomodulatory characteristics.
Introduction
Chronic rhinosinusitis (CRS) often occurs in association with nasal polyps (NP) in 4% of an entire population [1] and is associated with bronchial asthma (BA) in 7-13% of cases [2] and aspirin-exacerbated respiratory disease (AERD) and NP are present in 36-96% of patients [3] . In CRSwNP the predominate inflammatory cell is the eosinophil, which is found in both the tissue and in the airway mucus. The role of neutrophilic inflammation has been investigated but it does not seem to be a primary factor in the development of CRSwNP although the correlation with BA. Allergy seems to be a comorbid condition and not a primary factor in the development of CRSwNP [4] [5] [6] . At present, neither medical nor surgical treatment can ensure permanent control or enduring cure. Currently the only proven treatment for effective control of CRSwNP is topical nasal steroid sprays with or without systemic glucocorticosteroids (GCS). Recurrent CRSwNP is not always prevented even with systemic GCS and the side effects can be serious [7] . Because disease control can be difficult even with systemic GCS we decided to study treatment with ''long-term'' therapy using low dose macrolide antibiotics. The rational use of this drug does not reside in its antimicrobial properties as much as in its anti-inflammatory effects by inhibition of neutrophils and eosinophils. response, inhibiting polyp growth, destroying biofilms, and enhancing the protective properties of the respiratory tract mucosa [8] [9] [10] [11] . Macrolide effectiveness in patients with CRS without NP has been confirmed; however, their efficacy in CRSwNP patients has not been thoroughly investigated [4] . Therefore, our study was designed to evaluate the efficacy and safety of a long-term course of low-dose clarithromycin therapy in patients with CRSwNP after endoscopic sinus surgery (ESS) [12, 13] . Informed consent was obtained from each patient. Four patients were male and twelve female. All patients were examined with a fiberoptic and cranio-facial CT computerised tomography (CT). All 10 patients underwent bilateral ESS performed by the same surgeon. The nasal pack was removed the day after and the patient discharged. Seven days of antibiotics therapy amoxicillin/clavulanate combination, salin nasal irrigation and application of gomenolato oil spray was recommended. Patients were carefully followed and seen at 1 week intervals after ESS for medication. At 4-21 days after sugary (M = 18.1; SD = ? 3.06), patients showed resolution of scabs and scars, and therefore they were started on topical steroid (beclomethasone) and continued saline nasal irrigation. At 30-40 days after surgery (M = 35.04 SD = ± 4.33), patients reported a worsening of symptoms with onset of nasal obstruction; reductions/loss of smell; headache; high viscous secretions and therefore all patients continued therapy with saline nasal irrigation, topic steroid and started clarithromycin 500 mg/die for 3 days at week for 1 month.
Materials and Methods
Results of treatment were based on evaluation of 22-item SinoNasal Outcome Test (SNOT-22) and a score to the nasal endoscopy (endoscopic appearance score, EAS) recorded before and after therapy with clarithromycin.
The 20-item SinoNasal Outcome Test (SNOT-20) is a questionnaire for evaluating the quality of life (QoL) in rhinosinusitis patients [14] .
Endoscopy was performed with rigid fibreoptic endoscope 4 mm (Karl Storz, Tuttlingen, Germany) after decongestion of the nasal nostrils with cotton soaked in adrenaline and mepivacaine. EAS was given to the following endoscopic findings evaluated for both nasal cavities [15] : (1) the polyps were graded by size from 0 to 3 (0 = no polyps; 1 = polyps that appear only in the meatus medium; 2 = polyps extending beyond the middle meatus but not obstructing the nose; 3 = polyps completely obstructing the nose); (2) Discharge was scored as follows: 0 = no discharge; 1 = poor and clear discharge; 2 = dense and mucosal secretion; (3) the mucosal edema was assessed as follows: 0 = absent; 1 = mild; 2 = severe; (4) Postoperative Crusts and scars have received the following score: 0 = absent; 1 = mild; and 2 = severe.
Statistical Analysis
The results obtained were entered into a computerized database and processed using the statistical software package SPSS version 17.0 for Windows. T student signed rank tests were performed to evaluate significant difference before and after use of clarithromycin. Values were presented as means ± standard deviations. Results were considered statistically significant when p values were \0.05.
Results
90% (9/10) patients had BA, and 40% (4/10) presented with AERD. Atopy was confirmed by skin prick tests in 70% (7/10). Side effects related to clarithromycin were not evidenced. The results of the SNOT-22 and EAS evaluated before and after treatment with clarithromycin showed statistically significant improvements (p \ 0.05) for some parameters.
In particular, SNOT-22 showed an improvement about: blowing the nose (2.52 ± 0.87 vs. 1.3 ± 0.67), sneezing (2.1 ± 0.99 vs. 0.7 ± 0.94), hyposmia (3.1 ± 1.4 vs. 1.7 ± 1.49), dense mucous discharge (3.5 ± 1.17 vs. 1.5 ± 0.97) ( Table 1) . EAS evaluated before and after treatment with clarithromycin showed improvements in particular for two parameters: secretions (1.6 ± 0.69 vs. 0.3 ± 0.48) and edema (1.3 ± 0.48 vs. 0.2 ± 0.42) ( Table 2) .
6 months after treatment with clarithromycin, no patients reported a worsening of symptoms and the SNOT-22 and EAS showed no significant changes compared to those performed at the end of therapy with clarithromycin.
Discussion
Our results suggest that a prolonged treatment with lowdose claritromycin is effective when reserved for patients with recalcitrant CRS linked with BA and/or AERD and/or atopy in whom ESS associated with topical steroid therapy and nasal irrigation is not sufficient.
Although the mechanisms of CRSwP are not completely understood, the dysfunction of the mucosa of the paranasal sinuses seems to have a central role. The histopathological features of CRSwP are an increase of submucosal glands, a ciliated epithelium transformation in squamous epithelium and an infiltration of inflammatory cells such as neutrophils and eosinophils [16] . Fujita et al. [17] reported increased nasal concentration of IL-8 in cases with CRSwP compared to healthy subjects. In chronic rhinosinusitis, pus and viscous mucus in the sinuses together with bacteria act mucosal epithelium to produce pro-inflammatory cytokines such as IL-8. These cytokines induce a neutrophilic and eosinophilic infiltration, damage the ciliated epithelium and increasing the number of submucosal glands. This creates a vicious circle with chronic inflammation. Fujita et al. [17] has shown that the macrolide administered for 3 months significantly reduces the concentration of neutrophils, eosinophils and IL-8 in the nasal secretion. Wallwork et al. [18] , using roxithromycin 150 mg in patients with CRSwP, reported in the saccharine test a significant reduction from 11.5 to 8.2 min before and after treatment, demonstrating the recovery of mucociliary clearance. In spite of good results of macrolides therapy, literature is uniformly agreed to combine medical therapy with endoscopic sinus surgery normalizing pathological mucosa and removing the viscous mucus that contains bacteria and pro-inflammatory molecules. Inanli et al. [16] has conducted the test with saccharin, before and after surgery and showed that the mucociliary function significantly improved after surgery (respectively 12:15 min and 9:08 min before and after surgery). However, the ciliated epithelium was only partially restored, and the pathological mucosa was still present 3 months after surgery. Fang [19] did endoscopic examination of the epithelium of maxillary sinus in 121 patients and evaluated that the time necessary for its normalization was between 9 and 12 weeks, however, in 32 patients it took more than 12 weeks and in 16 it had not reached normalization with persistence of polyps and edema even after 16 weeks. It can be deduced that the regeneration of epithelium is still ongoing to 3-6 months after surgery. The reason for this slow recovery is the fact that the surgery itself causes a eosinophilic inflammation that often can not be adequately controlled with topical nasal steroids. In fact, Varvyanskaya and Lopatin studied the change of the levels of ECP (eosinophil cationic protein) in nasal secretions after FESS and after macrolide therapy. In the control group (not treated with macrolide) an increase of 3 times the average level ECP to 6 weeks after surgery while in the group treated with macrolide there was a gradual decrease in the levels of ECP [20] .
Therefore macrolide may reduce postoperative inflammation caused by the surgery, promote earliest possible normalization of pathological mucosa and improvement in symptoms.
Problem discussed in the literature is the correct duration of treatment with the macrolide (Table 3) . Kikuchi et al. [21] has shown that the long-term low-dose treatment with erythromycin 400-600 mg was effective in patients with symptomatic chronic sinusitis. In their study, the runny nose was reduced in 60% of cases, postnasal drip in 50%, nasal obstruction in 60% and headache in 100%. However, the duration of treatment has not been established (3-19 months) , and the average duration was 7.9 months. Subsequently, Hashiba and Baba [22] administered macrolide 400 mg for more than 12 weeks and showed an improvement in 70.6% of patients at 12 weeks but concluded that still remained uncertainty about the safety of the drug with a prolonged administration and that treatment should not be extended when the symptoms are relieved. The duration of treatment in the majority of subsequent studies was 3 months with results comparable to our protocol of 1 month of treatment even though the our short follow-up (6 months) not allow to establish how long the beneficial effects of macrolide are maintained. Nevertheless our clarithromycin protocol can be more manageable and can be used again whenever there is recurrence of symptoms. A prolonged treatment with the macrolide not only improves significantly symptoms such as nasal respiratory obstruction and headache and, therefore, a month of therapy is sufficient avoiding systemic corticosteroids (GS) that lead to different side effects.
The macrolide antibiotics are also excellent and have an important role not only in the treatment of Mycoplasma and Chlamydia but also in the eradication of Helicobacter pylori which has been reported as a cause of chronic gastritis. Furthermore a prolonged treatment with antibiotic can lead to antimicrobial resistance although currently in the literature was shown that there is not an increase of bacteria resistant to macrolides in cultures of samples taken from the middle meatus [23, 24] . 
Conclusion
The preliminary results of our study show that the low-dose clarithromycin for a period of 1 month can improve patients with eosinophilic chronic rhinosinusitis disorders not only through the antibacterial properties but also for the immunomodulatory characteristics. Using case-control double-blind study and a large size of cases, the efficacy of long term macrolide use in prevention of nasal polyposis recurrence after ESS needs to be determined and a treatment protocol has to be validated internationally for wider usage.
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